Compare DK & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DK | ABCL |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 2017 | 2020 |
| Metric | DK | ABCL |
|---|---|---|
| Price | $76.10 | $10.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 5 |
| Target Price | ★ $39.94 | $8.40 |
| AVG Volume (30 Days) | 1.5M | ★ 6.6M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | ★ 95.67 | 10.91 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $75,128,000.00 |
| Revenue This Year | $6.85 | N/A |
| Revenue Next Year | N/A | $21.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $25.85 | $2.75 |
| 52 Week High | $77.40 | $12.58 |
| Indicator | DK | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 61.95 | 50.98 |
| Support Level | $58.20 | $10.44 |
| Resistance Level | $77.40 | $12.58 |
| Average True Range (ATR) | 4.26 | 0.65 |
| MACD | 0.17 | -0.29 |
| Stochastic Oscillator | 77.92 | 0.70 |
Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. It has three segments: Refining segment and Logistics segment and retail segment. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.